Европейски съюз - италиански - EMA (European Medicines Agency)

mylan ireland limited - lenalidomide - mieloma multiplo - immunosoppressori - multiple myelomalenalidomide mylan as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide mylan as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant. lenalidomide mylan in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide mylan in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1-3a).

Европейски съюз - италиански - EMA (European Medicines Agency)

mylan ireland limited - rivaroxaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - agenti antitrombotici - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Италия - италиански - myHealthbox

mylan - paracalcitolo - soluzione iniettabile - 2 microgrammi/ml - agenti antiparatiroidei - paracalcitolo è indicato per la prevenzione ed il trattamento dell’iperparatiroidismo secondario nei pazienti affetti da insufficienza renale cronica sottoposti ad emodialisi.

Италия - италиански - myHealthbox

mylan - paracalcitolo - soluzione iniettabile - 5 microgrammi/ml - agenti antiparatiroidei - paracalcitolo è indicato per la prevenzione ed il trattamento dell’iperparatiroidismo secondario nei pazienti affetti da insufficienza renale cronica sottoposti ad emodialisi.

Италия - италиански - AIFA (Agenzia Italiana del Farmaco)

mylan s.p.a. - cabazitaxel - cabazitaxel

Италия - италиански - AIFA (Agenzia Italiana del Farmaco)

mylan s.p.a. - fosinopril - fosinopril

Италия - италиански - AIFA (Agenzia Italiana del Farmaco)

mylan s.p.a. - ganciclovir - ganciclovir

Италия - италиански - myHealthbox

mylan - rabeprazolo sodico - compressa gastroresistente - 20 mg - medicinali per ulcera peptidica e malattia da reflusso gastroesofageo (mrge), inibitori di pompa protonica - trattamento di: ulcera duodenale attiva, ulcera gastrica benigna attiva, malattia da reflusso gastroesofageo (mrge) sintomatica erosiva o ulcerativa, trattamento a lungo termine della malattia da reflusso gastroesofageo (mantenimento mrge), trattamento sintomatico della malattia da reflusso gastroesofageo da moderata a molto grave (mrge sintomatica), sindrome di zollinger-ellison.

Италия - италиански - myHealthbox

mylan - rabeprazolo sodico - compressa gastroresistente - 10 mg - medicinali per ulcera peptidica e malattia da reflusso gastroesofageo (mrge), inibitori di pompa protonica - trattamento di: ulcera duodenale attiva, ulcera gastrica benigna attiva, malattia da reflusso gastroesofageo (mrge) sintomatica erosiva o ulcerativa, trattamento a lungo termine della malattia da reflusso gastroesofageo (mantenimento mrge), trattamento sintomatico della malattia da reflusso gastroesofageo da moderata a molto grave (mrge sintomatica), sindrome di zollinger-ellison.

Италия - италиански - AIFA (Agenzia Italiana del Farmaco)

mylan s.p.a. - rabeprazolo - rabeprazolo